Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 102 in Advanced Renal Cell Carcinoma (Phase 2, Open-label, Single-agent)
2006-003785-33Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilotumumab in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC), sponsored by Amgen. Primary endpoint: objective response rate. Started Oct 2006; status: completed.
02
Drugs
rilotumumab
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2006-003785-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003785-33.